Literature DB >> 28874609

Modified Medical Research Council Dyspnea Scale in GOLD Classification Better Reflects Physical Activities of Daily Living.

Anelise B Munari1, Aline A Gulart1, Karoliny Dos Santos1, Raysa S Venâncio1, Manuela Karloh1, Anamaria F Mayer2.   

Abstract

BACKGROUND: In multidimensional Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, the choice of the symptom assessment instrument (modified Medical Research Council dyspnea scale [mMRC] or COPD assessment test [CAT]) can lead to a different distribution of patients in each quadrant. Considering that physical activities of daily living (PADL) is an important functional outcome in COPD, the objective of this study was to determine which symptom assessment instrument is more strongly associated with and differentiates better the PADL of patients with COPD.
METHODS: The study included 115 subjects with COPD (GOLD 2-4), who were submitted to spirometry, the mMRC, the CAT, and monitoring of PADL (triaxial accelerometer). Subjects were divided into 2 groups using the cutoffs proposed by the multidimensional GOLD classification: mMRC < 2 and ≥ 2 and CAT < 10 and ≥ 10.
RESULTS: Both mMRC and CAT reflected the PADL of COPD subjects. Subjects with mMRC < 2 and CAT < 10 spent less time in physical activities < 1.5 metabolic equivalents of task (METs) (mean of the difference [95% CI] = -62.9 [-94.4 to -31.4], P < .001 vs -71.0 [-116 to -25.9], P = .002) and had a higher number of steps (3,076 [1,999-4,153], P < .001 vs 2,688 [1,042-4,333], P = .002) than subjects with mMRC > 2 and CAT > 10, respectively. Physical activities ≥ 3 METs differed only between mMRC < 2 and mMRC ≥ 2 (39.2 [18.8-59.6], P < .001). Furthermore, only the mMRC was able to predict the PADL alone (time active, r2 = 0.16; time sedentary, r2 = 0.12; time ≥ 3 METs, r2 = 0.12) and associated with lung function (number of steps, r2 = 0.35; walking time, r2 = 0.37; time < 1.5 METs, r2 = 0.25).
CONCLUSIONS: The mMRC should be adopted as the classification criterion for symptom assessment in the GOLD ABCD system when focusing on PADL.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  GOLD classification; activities of daily living; chronic obstructive pulmonary disease; dyspnea; exercise; sedentary lifestyle; symptom assessment

Mesh:

Year:  2017        PMID: 28874609     DOI: 10.4187/respcare.05636

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  24 in total

1.  Does Nutritional Risk Screening 2002 Correlate with the Dyspnea Status of Patients with GOLD Stage C-D Chronic Obstructive Pulmonary Disease?

Authors:  Nalan Ogan; Fatma Yıldırım; Banu Süzen; Ayşe Baha; Evrim Eylem Akpınar
Journal:  Turk Thorac J       Date:  2020-01-01

2.  Comparison of Compliance Rates and Treatment Efficiency in Home-Based with Hospital-Based Pulmonary Rehabilitation in COPD.

Authors:  Esra Pehlivan; Esra Yazar; Arif Balcı; Lütfiye Kılıç
Journal:  Turk Thorac J       Date:  2019-07-01

3.  Exercise Capacity Is Independent of Respiratory Muscle Strength in Patients with Chronic Heart Failure.

Authors:  Ali Albarrati; Abdulrahman Aseeri; Mohammed Taher; Monira I Aldhahi; Rakan I Nazer
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

4.  Effectiveness of delivering integrated COPD care at public healthcare facilities: a cluster randomised trial in Pakistan.

Authors:  Muhammad Amir Khan; Nida Khan; John D Walley; Muhammad Ahmar Khan; Joseph Hicks; Maqsood Ahmed; Faisal Imtiaz Sheikh; Muhammad Ali; Farooq Manzoor; Haroon Jehangir Khan
Journal:  BJGP Open       Date:  2019-03-20

5.  Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study.

Authors:  Alex Kayongo; Adaeze C Wosu; Tasmia Naz; Faith Nassali; Robert Kalyesubula; Bruce Kirenga; Robert A Wise; Trishul Siddharthan; William Checkley
Journal:  COPD       Date:  2020-05-28       Impact factor: 2.409

6.  Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Ilaria Baiardini; Marco Contoli; Angelo Guido Corsico; Carla Scognamillo; Fabio Ferri; Nicola Scichilone; Paola Rogliani; Fabiano Di Marco; Pierachille Santus; Fulvio Braido
Journal:  Respiration       Date:  2021-03-11       Impact factor: 3.580

7.  Protocol for a single-centre mixed-method pre-post single-arm feasibility trial of a culturally appropriate 6-week pulmonary rehabilitation programme among adults with functionally limiting chronic respiratory diseases in Malawi.

Authors:  Fanuel Meckson Bickton; Talumba Mankhokwe; Rebecca Nightingale; Cashon Fombe; Martha Mitengo; Langsfield Mwahimba; Wilfred Lipita; Laura Wilde; Ilaria Pina; Zainab K Yusuf; Zahira Ahmed; Martin Kamponda; Felix Limbani; Harriet Shannon; Enock Chisati; Andy Barton; Robert C Free; Michael Steiner; Jesse A Matheson; Adrian Manise; Sally J Singh; Jamie Rylance; Mark Orme
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

8.  Evaluating an Intervention Program Using WeChat for Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.

Authors:  Yuyu Jiang; Fenglan Liu; Jianlan Guo; Pingping Sun; Zhongyi Chen; Jinping Li; Liming Cai; Hongqing Zhao; Ping Gao; Zhaosheng Ding; Xiaoliang Wu
Journal:  J Med Internet Res       Date:  2020-04-21       Impact factor: 5.428

9.  Disease awareness in patients with COPD: measurement and extent.

Authors:  Ilaria Baiardini; Paola Rogliani; Pierachille Santus; Angelo G Corsico; Marco Contoli; Nicola Scichilone; Fabiano Di Marco; Patrizia Lessi; Carla Scognamillo; Giorgia Molinengo; Fabio Ferri; Vincenzo Patella; Giuseppe Fiorentino; Mauro Carone; Fulvio Braido
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-17

10.  Improving acceptance and uptake of pulmonary rehabilitation after acute exacerbation of COPD: Acceptability, feasibility, and safety of a PR "taster" session delivered before hospital discharge.

Authors:  Siobhan Camille Milner; Jean Bourbeau; Sara Ahmed; Tania Janaudis-Ferreira
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.